BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24402625)

  • 1. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
    Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].
    Lidove O; Papo T
    Rev Med Interne; 2009 Oct; 30(10):920-9. PubMed ID: 19524334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety.
    Beck M
    Expert Opin Biol Ther; 2009 Feb; 9(2):255-61. PubMed ID: 19236256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
    Morel CF; Clarke JT
    Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease in children and the effects of enzyme replacement treatment.
    Pintos-Morell G; Beck M
    Eur J Pediatr; 2009 Nov; 168(11):1355-63. PubMed ID: 19242721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
    Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
    J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
    Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
    Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
    Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
    Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.
    Beck M
    Expert Opin Investig Drugs; 2002 Jun; 11(6):851-8. PubMed ID: 12036428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on role of agalsidase alfa in management of Fabry disease.
    Ramaswami U
    Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature.
    Lidove O; Joly D; Barbey F; Bekri S; Alexandra JF; Peigne V; Jaussaud R; Papo T
    Int J Clin Pract; 2007 Feb; 61(2):293-302. PubMed ID: 17263716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
    Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
    Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early therapeutic intervention in females with Fabry disease?
    Hughes DA
    Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.